9 results about "Benzylisoquinoline" patented technology

The invention discloses a benzylisoquinoline alkaloid glycoside compound as well as a preparation method and application thereof. The preparation method comprises the following steps: soaking tubers of rhizoma corydalis in a 6% acetic acid solution, crushing, soaking in water, and carrying out ultrasonic extraction to obtain a plant extract; after water dispersion, carrying out HPD100 type macroporous resin column chromatography separation, carrying out gradient elution by using ethanol aqueous solutions with different concentrations, and collecting a 50% ethanol elution part to obtain an elution part YH-D; carrying out MCI column chromatography separation, and carrying out gradient elution by using a 0-100% methanol-water solution to obtain four parts of eluents; the preparation method comprises the following steps: dissolving YH-D-2 in water, filtering, and carrying out medium-pressure ODS column chromatography separation, Sephadex LH-20 column chromatography separation, medium-pressure ODS column chromatography separation and semi-preparative C18 column HPLC (High Performance Liquid Chromatography) purification on the filtrate to obtain six new compounds 1-6. In-vitro experiments prove that the elution part YH-D-2 containing benzylisoquinoline alkaloid glycoside of the benzylisoquinoline alkaloid glycoside compounds 1-6 has NO generation inhibition activity, and has a good development prospect as an anti-inflammatory drug.

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

The present application relates to the technical field of plant genetic engineering, and specifically discloses a benzylisoquinoline alkaloid and derivative synthesis gene AcNMT3, a protein, an application, and a screening method. The screening method of the present application can accurately and effectively screen out the coding gene of nitrogen methyltransferase AcNMT3 in the synthesis pathway of the benzylisoquinoline alkaloid and derivative aristolochic acid of aristolochia contorta, and determine the encoded protein and function. AcNMT3 has the functions of catalyzing nornuciferine to generate N-methylnornuciferine, catalyzing nuciferine to generate N-methylnuciferine, catalyzing 3'-hydroxynuciferine to generate 3'-hydroxy-N-methylnuciferine, catalyzing N-methylnuciferine to generate magnoflorine, and catalyzing laurifoline to generate fujimorine, wherein the conversion efficiency of the secondary amine nitrogen to the tertiary amine nitrogen is the highest, so the main function is AcCNMT. The present application discloses one of the key enzymes in the synthesis of the benzylisoquinoline alkaloid of aristolochia contorta, and lays a foundation for the analysis of the biosynthesis pathway of the benzylisoquinoline alkaloid and derivative, the biosynthesis of the medicinal components, and the molecular breeding of aristolochia contorta.

The present invention discloses bis(benzylisoquinoline) alkaloid compounds, their synthesis, a combination and composition for activity against TLR4 receptors. The compounds of the present invention also show synergistic effect with other antibiotics.

The invention provides a benzyl isoquinoline alkaloid yarrowia lipolytica production strain and application thereof.The benzyl isoquinoline alkaloid yarrowia lipolytica production strain is a strain finally obtained through heterologous expression of CYP76AD5, DODC, NCS35, 6 'OMT, CNMT, NMCH and 4' OMT, deletion of HPPD, COMT, ADH2 and PAR4 genes and overexpression of ARO1, ARO2, Aro4K221L, Aro7G139S and ARO10, has the potential of being used as a microbial cell factory for producing BIA, and can be used as a microbial cell factory for producing BIA. (S)-higenamine and (S)-phylline can be synthesized from the beginning under the aerobic condition by using the YPD culture medium, and the synthesis efficiency and yield are remarkably improved.

The present invention provides pharmaceutical compositions and methods of use of bisbenzylisoquinoline, e.g., 6,6',7,12-tetramethoxy-2,2'-dimethyl-berbaman, and analogs, derivatives, isomers, and modified forms of the compound, e.g., in crystalline, salt, or salt form, in combination with pharmaceutically acceptable acids or other agents, for the treatment of acute, chronic, and preleukemic conditions, as well as lymphoma and solid tumors. These include, but are not limited to, preneoplastic and neoplastic diseases and solid tumors, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), atypical chronic myeloid leukemia (aCML), and acute myeloid leukemia (AML), polycythemia vera (PV), chronic lymphoblastic leukemia (CLL), myeloproliferative syndrome (MPS), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), myelofibrosis (MF), and polycythemia vera (PV).

To provide a method of epimerizing an (S)-1-benzylisoquinoline alkaloid to an (R)-1-benzylisoquinoline alkaloid.SOLUTION: The method comprises contacting the (S)-1-benzylisoquinoline alkaloid with at least one enzyme. Contacting the (S)-1-benzylisoquinoline alkaloid with the at least one enzyme converts the (S)-1-benzylisoquinoline alkaloid to an (R)-1-benzylisoquinoline alkaloid.SELECTED DRAWING: Figure 3

The invention discloses a novel benzylisoquinoline compound as well as a pharmaceutical composition and application thereof, and particularly provides a compound V as well as pharmaceutically acceptable salts, solvates, metabolites, tautomers or prodrugs thereof. The compound V comprises a compound shown in the formula I and pharmaceutically acceptable anions. The compound provided by the invention is relatively good in drug effect and good in application prospect.

The present application relates to a kind of from Bauhinia championii single benzyl isoquinoline alkaloid and its preparation method and application and pharmaceutical composition, the compound is tested to show certain pharmacological activity by opioid delta receptor target point, can be used in the drug development for preventing and / or treating pain and other diseases.The compound structure